{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:07:28Z","timestamp":1794049648192,"version":"4.8.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23DA052682"],"award-info":[{"award-number":["K23DA052682"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41380-026-03523-5","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T08:20:53Z","timestamp":1772180453000},"page":"3849-3871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Modulating the endocannabinoid system in alcohol use disorder: A translational systematic review and meta-analysis of preclinical and human studies"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8702-5436","authenticated-orcid":false,"given":"Gabriel P. A.","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayte A.","family":"Cerezo-Matias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6846-4846","authenticated-orcid":false,"given":"Melissa C.","family":"Funaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Bagdas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3153-1221","authenticated-orcid":false,"given":"Alfred","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6952-1726","authenticated-orcid":false,"given":"John","family":"Krystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismene","family":"Petrakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7357-8215","authenticated-orcid":false,"given":"Joao P.","family":"De Aquino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"3523_CR1","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0140-6736(19)31775-1","volume":"394","author":"AF Carvalho","year":"2019","unstructured":"Carvalho AF, Heilig M, Perez A, Probst C, Rehm J. Alcohol use disorders. Lancet. 2019;394:781\u201392.","journal-title":"Lancet"},{"key":"3523_CR2","volume-title":"2024 National Survey on Drug Use and Health: Table 5.9A\u2014Alcohol use disorder in past year: among people aged 12 or older; by age group and demographic characteristics, numbers in thousands, 2023 and 2024.","author":"Substance A, Mental Health Services A, Center for Behavioral Health S, Quality","year":"2025","unstructured":"Substance A, Mental Health Services A, Center for Behavioral Health S, Quality. 2024 National Survey on Drug Use and Health: Table 5.9A\u2014Alcohol use disorder in past year: among people aged 12 or older; by age group and demographic characteristics, numbers in thousands, 2023 and 2024. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2025."},{"key":"3523_CR3","unstructured":"Substance A, Mental Health Services Administration CfBHS, Quality. 2022 National Survey on Drug Use and Health. Table 5.9A\u2014Alcohol use disorder in past year: among people aged 12 or older; by age group and demographic characteristics, numbers in thousands, 2022 and 2023."},{"key":"3523_CR4","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.2023.19761","volume":"330","author":"M McPheeters","year":"2023","unstructured":"McPheeters M, O\u2019Connor EA, Riley S, Kennedy SM, Voisin C, Kuznacic K, et al. Pharmacotherapy for alcohol use disorder: A systematic review and meta-analysis. JAMA. 2023;330:1653\u201365.","journal-title":"JAMA"},{"key":"3523_CR5","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.biopsych.2006.09.038","volume":"61","author":"R Gueorguieva","year":"2007","unstructured":"Gueorguieva R, Wu R, Pittman B, Cramer J, Rosenheck RA, O\u2019Malley SS, et al. New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol Psychiatry. 2007;61:1290\u20135.","journal-title":"Biol Psychiatry"},{"key":"3523_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.drugalcdep.2009.10.017","volume":"107","author":"R Gueorguieva","year":"2010","unstructured":"Gueorguieva R, Wu R, Donovan D, Rounsaville BJ, Couper D, Krystal JH, et al. Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study. Drug Alcohol Depend. 2010;107:221\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"3523_CR7","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1111\/j.1460-9568.2008.06302.x","volume":"27","author":"F Alen","year":"2008","unstructured":"Alen F, Moreno-Sanz G, Isabel De Tena A, Brooks RD, Lopez-Jimenez A, Navarro M, et al. Pharmacological activation of CB1 and D2 receptors in rats: Predominant role of CB1 in the increase of alcohol relapse. Eur J Neurosci. 2008;27:3292\u20138.","journal-title":"Eur J Neurosci"},{"key":"3523_CR8","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","volume":"295","author":"RF Anton","year":"2006","unstructured":"Anton RF, O\u2019Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003\u201317.","journal-title":"JAMA"},{"key":"3523_CR9","doi-asserted-by":"publisher","first-page":"e87366","DOI":"10.1371\/journal.pone.0087366","volume":"9","author":"MD Skinner","year":"2014","unstructured":"Skinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS ONE. 2014;9:e87366.","journal-title":"PLoS ONE"},{"key":"3523_CR10","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2014.3628","volume":"311","author":"DE Jonas","year":"2014","unstructured":"Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis. JAMA. 2014;311:1889\u20131900.","journal-title":"JAMA"},{"key":"3523_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","volume":"79","author":"HC Lu","year":"2016","unstructured":"Lu HC, Mackie K. an introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79:516\u201325.","journal-title":"Biol Psychiatry"},{"key":"3523_CR12","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1046\/j.1460-9568.1999.00847.x","volume":"11","author":"G Marsicano","year":"1999","unstructured":"Marsicano G, Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci. 1999;11:4213\u201325.","journal-title":"Eur J Neurosci"},{"key":"3523_CR13","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41386-020-0606-2","volume":"45","author":"LM Best","year":"2020","unstructured":"Best LM, Williams B, Le Foll B, Mansouri E, Bazinet RP, Lin L, et al. Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [C-11]CURB. Neuropsychopharmacology. 2020;45:1289\u201396.","journal-title":"Neuropsychopharmacology"},{"key":"3523_CR14","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1523\/JNEUROSCI.0849-13.2014","volume":"34","author":"J Ceccarini","year":"2014","unstructured":"Ceccarini J, Hompes T, Verhaeghen A, Casteels C, Peuskens H, Bormans G, et al. Changes in cerebral CB1 receptor availability after acute and chronic alcohol abuse and monitored abstinence. J Neurosci. 2014;34:2822\u201331.","journal-title":"J Neurosci"},{"key":"3523_CR15","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.biopsych.2023.06.027","volume":"94","author":"JP De Aquino","year":"2023","unstructured":"De Aquino JP. Fatty acid amide hydrolase, neurodevelopment, and alcohol: Illuminating the intricacies of the endocannabinoid system in addiction susceptibility. Biol Psychiatry. 2023;94:e19\u2013e21.","journal-title":"Biol Psychiatry"},{"key":"3523_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.drugalcdep.2009.01.022","volume":"104","author":"CA Hartman","year":"2009","unstructured":"Hartman CA, Hopfer CJ, Haberstick B, Rhee SH, Crowley TJ, Corley RP, et al. The association between cannabinoid receptor 1 gene (CNR1) and cannabis dependence symptoms in adolescents and young adults. Drug Alcohol Depend. 2009;104:11\u201316.","journal-title":"Drug Alcohol Depend"},{"key":"3523_CR17","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/mp.2012.100","volume":"18","author":"J Hirvonen","year":"2013","unstructured":"Hirvonen J, Zanotti-Fregonara P, Umhau JC, George DT, Rallis-Frutos D, Lyoo CH, et al. Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography. Mol Psychiatry. 2013;18:916\u201321.","journal-title":"Mol Psychiatry"},{"key":"3523_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.alcohol.2012.01.002","volume":"46","author":"MJ Pava","year":"2012","unstructured":"Pava MJ, Woodward JJ. A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research. Alcohol. 2012;46:185\u2013204.","journal-title":"Alcohol"},{"key":"3523_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0376-8716(01)00164-8","volume":"65","author":"LG Schmidt","year":"2002","unstructured":"Schmidt LG, Samochowiec J, Finckh U, Fiszer-Piosik E, Horodnicki J, Wendel B, et al. Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend. 2002;65:221\u20134.","journal-title":"Drug Alcohol Depend"},{"key":"3523_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/acer.12989","volume":"40","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Huang T, Lee F, Kreek MJ. Involvement of endocannabinoids in alcohol \u201cBinge\u201d drinking: Studies of mice with human fatty acid amide hydrolase genetic variation and after CB1 receptor antagonists. Alcohol Clin Exp Res. 2016;40:467\u201373.","journal-title":"Alcohol Clin Exp Res"},{"key":"3523_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/npp.2015.166","volume":"41","author":"M Morena","year":"2016","unstructured":"Morena M, Patel S, Bains JS, Hill MN. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology. 2016;41:80\u2013102.","journal-title":"Neuropsychopharmacology"},{"key":"3523_CR22","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"3523_CR23","unstructured":"Reference Deduplicator. https:\/\/library.medicine.yale.edu\/reference-deduplicator, 2021, Accessed Date Accessed 2021 Accessed."},{"key":"3523_CR24","unstructured":"Risk Of Bias In Non-randomized Studies \u2013 of Interventions, Version 2 (ROBINS-I V2). https:\/\/www.riskofbias.info\/welcome\/robins-i-v2, 2024, Accessed Date Accessed 2024 Accessed."},{"key":"3523_CR25","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"3523_CR26","doi-asserted-by":"crossref","unstructured":"Metrik J, Aston ER, Gunn RL, Swift R, MacKillop J, Kahler CW. Acute effects of cannabis on alcohol craving and consumption: a randomized controlled crossover trial. Am J Psychiatry. 2026;183:134\u201343.","DOI":"10.1176\/appi.ajp.20250115"},{"key":"3523_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.neuroscience.2008.10.002","volume":"158","author":"F Alen","year":"2009","unstructured":"Alen F, Santos A, Moreno-Sanz G, Gonzalez-Cuevas G, Gine E, Franco-Ruiz L, et al. Cannabinoid-induced increase in relapse-like drinking is prevented by the blockade of the glycine-binding site of N-methyl-d-aspartate receptors. Neuroscience. 2009;158:465\u201373.","journal-title":"Neuroscience"},{"key":"3523_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2174\/1876523800902020077","volume":"2","author":"L Alvarez-Jaimes","year":"2009","unstructured":"Alvarez-Jaimes L, Polis I, Parsons LH. Regional influence of cannabinoid CB1 receptors in the regulation of ethanol self-administration by wistar rats. Open Neuropsychopharmacol J. 2009;2:77\u201385.","journal-title":"Open Neuropsychopharmacol J"},{"key":"3523_CR29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s002130050326","volume":"132","author":"M Arnone","year":"1997","unstructured":"Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl). 1997;132:104\u20136.","journal-title":"Psychopharmacology (Berl)"},{"key":"3523_CR30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.10.040","volume":"131","author":"A Balla","year":"2018","unstructured":"Balla A, Dong B, Shilpa BM, Vemuri K, Makriyannis A, Pandey SC, et al. Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling. Neuropharmacology. 2018;131:200\u20138.","journal-title":"Neuropharmacology"},{"key":"3523_CR31","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.pbb.2010.11.013","volume":"97","author":"ME Ballard","year":"2011","unstructured":"Ballard ME, De Wit H. Combined effects of acute, very-low-dose ethanol and delta(9)- tetrahydrocannabinol in healthy human volunteers. Pharmacol Biochem Behav. 2011;97:627\u201331.","journal-title":"Pharmacol Biochem Behav"},{"key":"3523_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/BF00434409","volume":"71","author":"KD Bird","year":"1980","unstructured":"Bird KD, Boleyn T, Chesher GB, Jackson DM, Starmer GA, Teo RKC. Intercannabinoid and cannabinoid-ethanol interactions and their effects on human performance. Psychopharmacology (Berl). 1980;71:181\u20138.","journal-title":"Psychopharmacology (Berl)"},{"key":"3523_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5694\/j.1326-5377.1976.tb134448.x","volume":"2","author":"GB Chesher","year":"1976","unstructured":"Chesher GB, Franks HM, Hensley VR. The interaction of ethanol and DELTA9 tetrahydrocannabinol in man: effects on perceptual, cognitive and motor functions. Med J Aust. 1976;2:159\u201363.","journal-title":"Med J Aust"},{"key":"3523_CR34","doi-asserted-by":"publisher","first-page":"478","DOI":"10.5694\/j.1326-5377.1977.tb130831.x","volume":"1","author":"GB Chesher","year":"1977","unstructured":"Chesher GB, Franks HM, Jackson DM. Ethanol and DELTA9 tetrahydrocannabinol. Interactive effects on human perceptual, cognitive and motor functions. II. Med J Aust. 1977;1:478\u201381.","journal-title":"Med J Aust"},{"key":"3523_CR35","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/j.1460-9568.2007.05665.x","volume":"26","author":"A Cippitelli","year":"2007","unstructured":"Cippitelli A, Bilbao A, Gorriti MA, Navarro M, Massi M, Piomelli D, et al. The anandamide transport inhibitor AM404 reduces ethanol self-administration. Eur J Neurosci. 2007;26:476\u201386.","journal-title":"Eur J Neurosci"},{"key":"3523_CR36","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1111\/j.1460-9568.2005.04056.x","volume":"21","author":"A Cippitelli","year":"2005","unstructured":"Cippitelli A, Bilbao A, Hansson AC, Del Arco I, Sommer W, Heilig M, et al. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur J Neurosci. 2005;21:2243\u201351.","journal-title":"Eur J Neurosci"},{"key":"3523_CR37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/oxfordjournals.alcalc.a008368","volume":"33","author":"G Colombo","year":"1998","unstructured":"Colombo G, Agabio R, Fa M, Guano L, Lobina C, Loche A, et al. Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716. Alcohol Alcohol. 1998;33:126\u201330.","journal-title":"Alcohol Alcohol"},{"key":"3523_CR38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/BF00431988","volume":"66","author":"P Consroe","year":"1979","unstructured":"Consroe P, Carlini EA, Zwicker AP, Lacerda LA. Interaction of cannabidiol and alcohol in humans. Psychopharmacology (Berl). 1979;66:45\u201350.","journal-title":"Psychopharmacology (Berl)"},{"key":"3523_CR39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.bbr.2010.11.013","volume":"217","author":"NMWJ de Bruin","year":"2011","unstructured":"de Bruin NMWJ, Lange JHM, Kruse CG, Herremans AH, Schoffelmeer ANM, van Drimmelen M, et al. SLV330, a cannabinoid CB1 receptor antagonist, attenuates ethanol and nicotine seeking and improves inhibitory response control in rats. Behav Brain Res. 2011;217:408\u201315.","journal-title":"Behav Brain Res"},{"key":"3523_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108623","volume":"195","author":"RS Dulman","year":"2021","unstructured":"Dulman RS, Zhang H, Banerjee R, Krishnan HR, Dong B, Hungund BL, et al. CB1 receptor neutral antagonist treatment epigenetically increases neuropeptide Y expression and decreases alcohol drinking. Neuropharmacology. 2021;195:108623.","journal-title":"Neuropharmacology"},{"key":"3523_CR41","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s00213-005-0199-9","volume":"183","author":"D Economidou","year":"2006","unstructured":"Economidou D, Mattioli L, Cifani C, Perfumi M, Massi M, Cuomo V, et al. Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology (Berl). 2006;183:394\u2013403.","journal-title":"Psychopharmacology (Berl)"},{"key":"3523_CR42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0014-2999(99)00170-3","volume":"370","author":"JE Gallate","year":"1999","unstructured":"Gallate JE, Saharov T, Mallet PE, McGregor IS. Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. Eur J Pharmacol. 1999;370:233\u201340.","journal-title":"Eur J Pharmacol"},{"key":"3523_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109549","volume":"233","author":"A Gasparyan","year":"2023","unstructured":"Gasparyan A, Navarrete F, Navarro D, Manzanares J. Cannabidiol regulates behavioral and brain alterations induced by spontaneous alcohol withdrawal. Neuropharmacology. 2023;233:109549.","journal-title":"Neuropharmacology"},{"key":"3523_CR44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00213-009-1704-3","volume":"208","author":"DT George","year":"2010","unstructured":"George DT, Herion DW, Jones CL, Phillips MJ, Hersh J, Hill D, et al. Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. Psychopharmacology (Berl). 2010;208:37\u201344.","journal-title":"Psychopharmacology (Berl)"},{"key":"3523_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/alcalc\/agh114","volume":"40","author":"GL Gessa","year":"2005","unstructured":"Gessa GL, Serra S, Vacca G, Carai MAM, Colombo G. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol Alcohol. 2005;40:46\u201353.","journal-title":"Alcohol Alcohol"},{"key":"3523_CR46","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.pbb.2010.11.006","volume":"97","author":"B Getachew","year":"2011","unstructured":"Getachew B, Hauser SR, Dhaher R, Katner SN, Bell RL, Oster SM, et al. CB1 receptors regulate alcohol-seeking behavior and alcohol self-administration of alcohol-preferring (P) rats. Pharmacol Biochem Behav. 2011;97:669\u201375.","journal-title":"Pharmacol Biochem Behav"},{"key":"3523_CR47","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/00008877-200605000-00006","volume":"17","author":"BC Ginsburg","year":"2006","unstructured":"Ginsburg BC, Lamb RJ. Cannabinoid effects on behaviors maintained by ethanol or food: A within-subjects comparison. Behav Pharmacol. 2006;17:249\u201357.","journal-title":"Behav Pharmacol"},{"key":"3523_CR48","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41386-018-0050-8","volume":"43","author":"G Gonzalez-Cuevas","year":"2018","unstructured":"Gonzalez-Cuevas G, Martin-Fardon R, Kerr TM, Stouffer DG, Parsons LH, Hammell DC, et al. Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle. Neuropsychopharmacology. 2018;43:2036\u201345.","journal-title":"Neuropsychopharmacology"},{"key":"3523_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2020.110141","volume":"106","author":"S Hamidullah","year":"2021","unstructured":"Hamidullah S, Lutelmowski CD, Creighton SD, Luciani KR, Frie JA, Winters BD, et al. Effects of vapourized THC and voluntary alcohol drinking during adolescence on cognition, reward, and anxiety-like behaviours in rats. Prog Neuro-Psychopharmacol Biol Psychiatry. 2021;106:110141.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"3523_CR50","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00213-023-06349-z","volume":"240","author":"HC Karoly","year":"2023","unstructured":"Karoly HC, Drennan ML, Prince MA, Zulic L, Dooley G. Consuming oral cannabidiol prior to a standard alcohol dose has minimal effect on breath alcohol level and subjective effects of alcohol. Psychopharmacology (Berl). 2023;240:1119\u201329.","journal-title":"Psychopharmacology (Berl)"},{"key":"3523_CR51","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1037\/adb0000706","volume":"35","author":"HC Karoly","year":"2021","unstructured":"Karoly HC, Mueller RL, Andrade CC, Hutchison KE. THC and CBD effects on alcohol use among alcohol and Cannabis Co-Users. Psychol Addict Behav. 2021;35:749\u201359.","journal-title":"Psychol Addict Behav"},{"key":"3523_CR52","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/BF01919854","volume":"32","author":"PM Kralik","year":"1976","unstructured":"Kralik PM, Ho BT, Matthews HR. Effect of DELTA9 THC on ethanol withdrawal in mice. Experientia. 1976;32:723\u20135.","journal-title":"Experientia"},{"key":"3523_CR53","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.alcohol.2006.08.001","volume":"39","author":"F Lallemand","year":"2006","unstructured":"Lallemand F, De Witte P. SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats. Alcohol. 2006;39:125\u201334.","journal-title":"Alcohol"},{"key":"3523_CR54","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/alcalc\/agh098","volume":"39","author":"F Lallemand","year":"2004","unstructured":"Lallemand F, Soubrie P, De Witte P. Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic alcohol administration combined with repeated re-exposures and withdrawals. Alcohol Alcohol. 2004;39:486\u201392.","journal-title":"Alcohol Alcohol"},{"key":"3523_CR55","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1111\/j.1530-0277.2001.tb02353.x","volume":"25","author":"F Lallemand","year":"2001","unstructured":"Lallemand F, Soubrie PH, De Witte PH. Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration. Alcohol: Clin Exp Res. 2001;25:1317\u201323.","journal-title":"Alcohol: Clin Exp Res"},{"key":"3523_CR56","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1017\/S1461145709991118","volume":"13","author":"F Al\u00e9n","year":"2010","unstructured":"Al\u00e9n F, Mouret A, Viveros M-P, Llorente R, Lepousez G, Lledo P-M, et al. Converging action of alcohol consumption and cannabinoid receptor activation on adult hippocampal neurogenesis. Int J Neuropsychopharmacol. 2010;13:191\u2013205.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3523_CR57","doi-asserted-by":"publisher","first-page":"8245","DOI":"10.1523\/JNEUROSCI.2179-04.2004","volume":"24","author":"JA Lopez-Moreno","year":"2004","unstructured":"Lopez-Moreno JA, Gonzalez-Cuevas G, Rodriguez De Fonseca F, Navarro M. Long-lasting increase of alcohol relapse by the cannabinoid receptor agonist WIN 55,212-2 during alcohol deprivation. J Neurosci. 2004;24:8245\u201352.","journal-title":"J Neurosci"},{"key":"3523_CR58","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1124\/jpet.121.000919","volume":"380","author":"DF Lovelock","year":"2022","unstructured":"Lovelock DF, Nguyen T, Van Voorhies K, Zhang Y, Besheer J. RTICBM-74 is a brain-penetrant cannabinoid receptor Subtype 1 allosteric modulator that reduces alcohol intake in rats. J Pharmacol Exp Ther. 2022;380:153\u201361.","journal-title":"J Pharmacol Exp Ther"},{"key":"3523_CR59","first-page":"77","volume":"7","author":"SE Lukas","year":"1992","unstructured":"Lukas SE, Benedikt R, Mendelson JH, Kouri E, Sholar M, Amass L. Marihuana attenuates the rise in plasma ethanol levels in human subjects. Neuropsychopharmacology. 1992;7:77\u201381.","journal-title":"Neuropsychopharmacology"},{"key":"3523_CR60","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1089\/can.2020.0132","volume":"7","author":"P MacCioni","year":"2022","unstructured":"MacCioni P, Bratzu J, Carai MAM, Colombo G, Gessa GL. Reducing effect of cannabidiol on alcohol self-administration in sardinian alcohol-preferring rats. Cannabis Cannabinoid Res. 2022;7:161\u20139.","journal-title":"Cannabis Cannabinoid Res"},{"key":"3523_CR61","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/1876523800902020040","volume":"2","author":"P Maccioni","year":"2009","unstructured":"Maccioni P, Fantini N, Carai MAM, Gessa GL, Colombo G. Suppressing effect of the cannabinoid CB1 receptor antagonist, rimonabant, on alcohol self-administration in alcohol-preferring rats. Open Neuropsychopharmacol J. 2009;2:40\u201344.","journal-title":"Open Neuropsychopharmacol J"},{"key":"3523_CR62","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1111\/j.1530-0277.2008.00786.x","volume":"32","author":"H Malinen","year":"2008","unstructured":"Malinen H, Hyytia P. Ethanol self-administration is regulated by CB1 receptors in the nucleus accumbens and ventral tegmental area in alcohol-preferring AA rats. Alcohol: Clin Exp Res. 2008;32:1976\u201383.","journal-title":"Alcohol: Clin Exp Res"},{"key":"3523_CR63","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0376-8716(91)90009-N","volume":"27","author":"DE McMillan","year":"1991","unstructured":"McMillan DE, Snodgrass SH. Effects of acute and chronic administration of DELTA9-tetrahy-drocannabinol or cocaine on ethanol intake in a rat model. Drug Alcohol Depend. 1991;27:263\u201374.","journal-title":"Drug Alcohol Depend"},{"key":"3523_CR64","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fnins.2024.1375440","volume":"18","author":"M Melkumyan","year":"2024","unstructured":"Melkumyan M, Annaswamy VM, Evans AM, Showemimo OF, McCullers ZE, Sun DX, et al. Effects of cannabidiol, with and without \u03949-tetrahydrocannabinol, on anxiety-like behavior following alcohol withdrawal in mice. Front Neurosci. 2024;18:17.","journal-title":"Front Neurosci"},{"key":"3523_CR65","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.bcp.2018.07.041","volume":"157","author":"F Navarrete","year":"2018","unstructured":"Navarrete F, Garcia-Gutierrez MS, Manzanares J. Pharmacological regulation of cannabinoid CB2 receptor modulates the reinforcing and motivational actions of ethanol. Biochem Pharmacol. 2018;157:227\u201334.","journal-title":"Biochem Pharmacol"},{"key":"3523_CR66","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00213-023-06500-w","volume":"241","author":"JG Raghav","year":"2024","unstructured":"Raghav JG, Kumar H, Ji L, Vemuri K, Makriyannis A, Suh J, et al. The neutral CB1 antagonist AM6527 reduces ethanol seeking, binge-like consumption, reinforcing, and withdrawal effects in male and female mice. Psychopharmacology (Berl). 2024;241:427\u201343.","journal-title":"Psychopharmacology (Berl)"},{"key":"3523_CR67","first-page":"1109","volume":"20","author":"F Rodriguez De Fonseca","year":"1999","unstructured":"Rodriguez De Fonseca F, Roberts AJ, Bilbao A, Koob GF, Navarro M. Cannabinoid receptor antagonist SR141716A decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers. Acta Pharmacol Sin. 1999;20:1109\u201314.","journal-title":"Acta Pharmacol Sin"},{"key":"3523_CR68","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.neuropharm.2008.02.005","volume":"54","author":"M Rubio","year":"2008","unstructured":"Rubio M, Fernandez-Ruiz J, de Miguel R, Maestro B, Michael Walker J, Ramos JA. CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats. Neuropharmacology. 2008;54:976\u201388.","journal-title":"Neuropharmacology"},{"key":"3523_CR69","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.3390\/molecules26165089","volume":"26","author":"L Santos-Molina","year":"2021","unstructured":"Santos-Molina L, Herrerias A, Zawatsky CN, Gunduz-Cinar O, Cinar R, Iyer MR, et al. Effects of a peripherally restricted hybrid inhibitor of CB1 receptors and iNOS on alcohol drinking behavior and alcohol-induced endotoxemia. Molecules (Basel, Switzerland). 2021;26:5089.","journal-title":"Molecules (Basel, Switzerland)"},{"key":"3523_CR70","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0014-2999(02)01594-7","volume":"443","author":"S Serra","year":"2002","unstructured":"Serra S, Brunetti G, Pani M, Vacca G, Carai MAM, Gessa GL, et al. Blockade by the cannabinoid CB1 receptor antagonist, SR 141716, of alcohol deprivation effect in alcohol-preferring rats. Eur J Pharmacol. 2002;443:95\u201397.","journal-title":"Eur J Pharmacol"},{"key":"3523_CR71","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/JCP.0b013e318172b8bc","volume":"28","author":"M Soyka","year":"2008","unstructured":"Soyka M, Koller G, Schmidt P, Lesch OM, Leweke M, Fehr C, et al. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: Results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol. 2008;28:317\u201324.","journal-title":"J Clin Psychopharmacol"},{"key":"3523_CR72","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.1002\/ptr.7972","volume":"37","author":"G Tringali","year":"2023","unstructured":"Tringali G, Lavanco G, Castelli V, Pizzolanti G, Kuchar M, Curro D, et al. Cannabidiol tempers alcohol intake and neuroendocrine and behavioural correlates in alcohol binge drinking adolescent rats. Focus on calcitonin gene-related peptide\u2019s brain levels. Phytother Res. 2023;37:4870\u201384.","journal-title":"Phytother Res"},{"key":"3523_CR73","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1037\/pha0000621","volume":"31","author":"A Venegas","year":"2023","unstructured":"Venegas A, Ray LA. Cross-Substance primed and cue-induced craving among alcohol and cannabis co-users: An experimental psychopharmacology approach. Exp Clin Psychopharmacol. 2023;31:683\u201393.","journal-title":"Exp Clin Psychopharmacol"},{"key":"3523_CR74","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/syn.20533","volume":"62","author":"KY Vinod","year":"2008","unstructured":"Vinod KY, Yalamanchili R, Thanos PK, Vadasz C, Cooper TB, Volkow ND, et al. Genetic and pharmacological manipulations of the CB1 receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice. Synapse. 2008;62:574\u201381.","journal-title":"Synapse"},{"key":"3523_CR75","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1111\/bph.14380","volume":"175","author":"A Viudez-Martinez","year":"2018","unstructured":"Viudez-Martinez A, Garcia-Gutierrez MS, Fraguas-Sanchez AI, Torres-Suarez AI, Manzanares J. Effects of cannabidiol plus naltrexone on motivation and ethanol consumption. Br J Pharmacol. 2018;175:3369\u201378.","journal-title":"Br J Pharmacol"},{"key":"3523_CR76","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12765","volume":"25","author":"A Viudez-Martinez","year":"2020","unstructured":"Viudez-Martinez A, Garcia-Gutierrez MS, Manzanares J. Gender differences in the effects of cannabidiol on ethanol binge drinking in mice. Addict Biol. 2020;25:e12765.","journal-title":"Addict Biol"},{"key":"3523_CR77","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/adb.12495","volume":"23","author":"A Viudez-Martinez","year":"2018","unstructured":"Viudez-Martinez A, Garcia-Gutierrez MS, Navarron CM, Morales-Calero MI, Navarrete F, Torres-Suarez AI, et al. Cannabidiol reduces ethanol consumption, motivation and relapse in mice. Addict Biol. 2018;23:154\u201364.","journal-title":"Addict Biol"},{"key":"3523_CR78","doi-asserted-by":"publisher","first-page":"e0140501","DOI":"10.1371\/journal.pone.0140501","volume":"10","author":"MC Wardle","year":"2015","unstructured":"Wardle MC, Marcus BA, de Wit H. A preliminary Investigation of individual differences in subjective responses to damphetamine, alcohol, and delta-9-tetrahydrocannabinol using a within-subjects randomized trial. PLoS ONE. 2015;10:e0140501.","journal-title":"PLoS ONE"},{"key":"3523_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2022.110570","volume":"118","author":"CM Wickens","year":"2022","unstructured":"Wickens CM, Wright M, Mann RE, Brands B, Di Ciano P, Stoduto G, et al. Separate and combined effects of alcohol and cannabis on mood, subjective experience, cognition and psychomotor performance: A randomized trial. Prog Neuro-Psychopharmacol Biol Psychiatry. 2022;118:110570.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"3523_CR80","doi-asserted-by":"publisher","DOI":"10.1172\/JCI146861","volume":"131","author":"ND Winters","year":"2021","unstructured":"Winters ND, Bedse G, Astafyev AA, Patrick TA, Altemus M, Morgan AJ, et al. Targeting diacylglycerol lipase reduces alcohol consumption in preclinical models. J Clin Invest. 2021;131:e146861.","journal-title":"J Clin Invest"},{"key":"3523_CR81","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1007\/s00213-017-4691-9","volume":"234","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Schwartz BI, Giza J, Gross SS, Lee FS, Kreek MJ. Blockade of alcohol escalation and \u201crelapse\u201d drinking by pharmacological FAAH inhibition in male and female C57BL\/6J mice. Psychopharmacology (Berl). 2017;234:2955\u201370.","journal-title":"Psychopharmacology (Berl)"},{"key":"3523_CR82","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/s41380-024-02869-y","volume":"30","author":"S Zimmermann","year":"2025","unstructured":"Zimmermann S, Teetzmann A, Bae\u00dfler J, Schreckenberger L, Zaiser J, Pfisterer M, et al. Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: the double-blind randomized controlled ICONIC trial. Mol Psychiatry. 2025;30:2612\u20139.","journal-title":"Mol Psychiatry"},{"key":"3523_CR83","doi-asserted-by":"crossref","unstructured":"Dirik S, Doyle MR, Wood CP, Campo P, Martinez AR, Fannon M, et al. Cannabidiol mitigates alcohol dependence and withdrawal with neuroprotective effects in the basolateral amygdala and striatum. Neuropsychopharmacology. 2026;51:691\u2013702.","DOI":"10.1038\/s41386-025-02164-6"},{"key":"3523_CR84","doi-asserted-by":"crossref","unstructured":"Hurzeler T, Logge W, Watt J, McGregor IS, Suraev A, Haber PS, et al. Cannabidiol attenuates precuneus activation during appetitive cue exposure in individuals with alcohol use disorder. Eur Arch Psychiatry Clin Neurosci. 2025;275:2129\u201339.","DOI":"10.1007\/s00406-025-01983-4"},{"key":"3523_CR85","doi-asserted-by":"crossref","unstructured":"Kirkland AE, Browning BD, Meredith LR, Robertson E, Herring C, Tomko RL, et al. The neural and psychophysiological effects of cannabidiol in youth with alcohol use disorder: A randomized controlled clinical trial. Neuropsychopharmacology. 2025;50:1482\u201392.","DOI":"10.1038\/s41386-025-02141-z"},{"key":"3523_CR86","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/acer.15514","volume":"49","author":"T Hurzeler","year":"2025","unstructured":"Hurzeler T, Logge W, Watt J, McGregor IS, Suraev A, Haber PS, et al. Cannabidiol alters psychophysiological, craving and anxiety responses in an alcohol cue reactivity task: A cross-over randomized controlled trial. Alcohol Clin Exp Res (Hoboken). 2025;49:448\u201359.","journal-title":"Alcohol Clin Exp Res (Hoboken)"},{"key":"3523_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1516351","volume":"16","author":"RL Mueller","year":"2025","unstructured":"Mueller RL, Hooper JF, Ellingson JM, Olsavsky AK, Rzasa-Lynn R, Bryan AD, et al. A preliminary randomized trial of the safety, tolerability, and clinical effects of hemp-derived cannabidiol in alcohol use disorder. Front Psychiatry. 2025;16:1516351.","journal-title":"Front Psychiatry"},{"key":"3523_CR88","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1124\/jpet.112.201962","volume":"344","author":"BD Kangas","year":"2013","unstructured":"Kangas BD, Delatte MS, Vemuri VK, Thakur GA, Nikas SP, Subramanian KV, et al. Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists. J Pharmacol Exp Ther. 2013;344:561\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"3523_CR89","doi-asserted-by":"publisher","first-page":"241","DOI":"10.31887\/DCNS.2020.22.3\/rspanagel","volume":"22","author":"R Spanagel","year":"2020","unstructured":"Spanagel R. Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions. Dialogues Clin Neurosci. 2020;22:241\u201350.","journal-title":"Dialogues Clin Neurosci"},{"key":"3523_CR90","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fpsyt.2014.00092","volume":"5","author":"G Panagis","year":"2014","unstructured":"Panagis G, Mackey B, Vlachou S. Cannabinoid regulation of brain reward processing with an emphasis on the role of CB1 receptors: A step back into the future. Front Psychiatry. 2014;5:92.","journal-title":"Front Psychiatry"},{"key":"3523_CR91","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1523\/JNEUROSCI.1486-22.2023","volume":"43","author":"SZ Bacharach","year":"2023","unstructured":"Bacharach SZ, Martin DA, Stapf CA, Sun F, Li Y, Cheer JF, et al. Decreased ventral tegmental area CB1R signaling reduces sign tracking and shifts cue-outcome dynamics in rat nucleus accumbens. J Neurosci. 2023;43:4684\u201396.","journal-title":"J Neurosci"},{"key":"3523_CR92","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00213-020-05712-8","volume":"238","author":"SC Britch","year":"2021","unstructured":"Britch SC, Babalonis S, Walsh SL. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl). 2021;238:9\u201328.","journal-title":"Psychopharmacology (Berl)"},{"key":"3523_CR93","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172:4790\u2013805.","journal-title":"Br J Pharmacol"},{"key":"3523_CR94","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00213-008-1168-x","volume":"199","author":"AC Campos","year":"2008","unstructured":"Campos AC, Guimar\u00e3es FS. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl). 2008;199:223\u201330.","journal-title":"Psychopharmacology (Berl)"},{"key":"3523_CR95","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","volume":"367","author":"AC Campos","year":"2012","unstructured":"Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimar\u00e3es FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012;367:3364\u201378.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"3523_CR96","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.2147\/JPR.S258433","volume":"13","author":"U Anand","year":"2020","unstructured":"Anand U, Jones B, Korchev Y, Bloom SR, Pacchetti B, Anand P, et al. CBD Effects on TRPV1 Signaling Pathways in Cultured DRG Neurons. J Pain Res. 2020;13:2269\u201378.","journal-title":"J Pain Res"},{"key":"3523_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01615-0","volume":"11","author":"SJ Nieto","year":"2021","unstructured":"Nieto SJ, Grodin EN, Aguirre CG, Izquierdo A, Ray LA. Translational opportunities in animal and human models to study alcohol use disorder. Transl Psychiatry. 2021;11:496.","journal-title":"Transl Psychiatry"},{"key":"3523_CR98","first-page":"77","volume":"24","author":"B Tabakoff","year":"2000","unstructured":"Tabakoff B, Hoffman PL. Animal models in alcohol research. Alcohol Res Health. 2000;24:77\u201384.","journal-title":"Alcohol Res Health"},{"key":"3523_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13724-x","volume":"12","author":"S Chou","year":"2022","unstructured":"Chou S, Ranganath T, Fish KN, Lewis DA, Sweet RA. Cell type specific cannabinoid CB1 receptor distribution across the human and non-human primate cortex. Sci Rep. 2022;12:9605.","journal-title":"Sci Rep"},{"key":"3523_CR100","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.neuroscience.2010.06.011","volume":"169","author":"SM Eggan","year":"2010","unstructured":"Eggan SM, Melchitzky DS, Sesack SR, Fish KN, Lewis DA. Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience. 2010;169:1651\u201361.","journal-title":"Neuroscience"},{"key":"3523_CR101","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/sj.bjp.0707399","volume":"152","author":"JM McPartland","year":"2007","unstructured":"McPartland JM, Glass M, Pertwee RG. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol. 2007;152:583\u201393.","journal-title":"Br J Pharmacol"},{"key":"3523_CR102","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1001\/archpsyc.58.4.322","volume":"58","author":"MA Huestis","year":"2001","unstructured":"Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry. 2001;58:322\u20138.","journal-title":"Arch Gen Psychiatry"},{"key":"3523_CR103","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","volume":"370","author":"R Christensen","year":"2007","unstructured":"Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370:1706\u201313.","journal-title":"Lancet"},{"key":"3523_CR104","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.physbeh.2007.11.007","volume":"93","author":"J Bergman","year":"2008","unstructured":"Bergman J, Delatte MS, Paronis CA, Vemuri K, Thakur GA, Makriyannis A. Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. Physiol Behav. 2008;93:666\u201370.","journal-title":"Physiol Behav"},{"key":"3523_CR105","doi-asserted-by":"publisher","first-page":"pyw068","DOI":"10.1093\/ijnp\/pyw068","volume":"19","author":"AB Gueye","year":"2016","unstructured":"Gueye AB, Pryslawsky Y, Trigo JM, Poulia N, Delis F, Antoniou K, et al. The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimonabant for nicotine dependence and weight loss with better psychiatric tolerability. Int J Neuropsychopharmacol. 2016;19:pyw068.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3523_CR106","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.2174\/1568026619666190708164841","volume":"19","author":"T Nguyen","year":"2019","unstructured":"Nguyen T, Thomas BF, Zhang Y. Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: Current approaches for therapeutics development. Curr Top Med Chem. 2019;19:1418\u201335.","journal-title":"Curr Top Med Chem"},{"key":"3523_CR107","doi-asserted-by":"publisher","first-page":"9406","DOI":"10.1073\/pnas.0914661107","volume":"107","author":"MN Hill","year":"2010","unstructured":"Hill MN, McLaughlin RJ, Bingham B, Shrestha L, Lee TT, Gray JM, et al. Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci USA. 2010;107:9406\u201311.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3523_CR108","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1038\/npp.2013.153","volume":"38","author":"A Blasio","year":"2013","unstructured":"Blasio A, Iemolo A, Sabino V, Petrosino S, Steardo L, Rice KC, et al. Rimonabant precipitates anxiety in rats withdrawn from palatable food: Role of the central amygdala. Neuropsychopharmacology. 2013;38:2498\u2013507.","journal-title":"Neuropsychopharmacology"},{"key":"3523_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2020.112697","volume":"390","author":"R Ettaro","year":"2020","unstructured":"Ettaro R, Laudermilk L, Clark SD, Maitra R. Behavioral assessment of rimonabant under acute and chronic conditions. Behav Brain Res. 2020;390:112697.","journal-title":"Behav Brain Res"},{"key":"3523_CR110","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1476-5381.2010.00885.x","volume":"161","author":"CL Limebeer","year":"2010","unstructured":"Limebeer CL, Vemuri VK, Bedard H, Lang ST, Ossenkopp KP, Makriyannis A, et al. Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. Br J Pharmacol. 2010;161:336\u201349.","journal-title":"Br J Pharmacol"},{"key":"3523_CR111","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1089\/can.2023.0246","volume":"9","author":"LC Gowatch","year":"2024","unstructured":"Gowatch LC, Evanski JM, Ely SL, Zundel CG, Bhogal A, Carpenter C, et al. Endocannabinoids and stress-related neurospsychiatric disorders: A systematic review and meta-analysis of basal concentrations and response to acute psychosocial stress. Cannabis Cannabinoid Res. 2024;9:1217\u201334.","journal-title":"Cannabis Cannabinoid Res"},{"key":"3523_CR112","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/nrn4036","volume":"16","author":"B Lutz","year":"2015","unstructured":"Lutz B, Marsicano G, Maldonado R, Hillard CJ. The endocannabinoid system in guarding against fear, anxiety and stress. Nat Rev Neurosci. 2015;16:705\u201318.","journal-title":"Nat Rev Neurosci"},{"key":"3523_CR113","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","volume":"72","author":"BF Grant","year":"2015","unstructured":"Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of DSM-5 alcohol use disorder: Results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiatry. 2015;72:757\u201366.","journal-title":"JAMA Psychiatry"},{"key":"3523_CR114","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/bcpt.13710","volume":"130","author":"J Peng","year":"2022","unstructured":"Peng J, Fan M, An C, Ni F, Huang W, Luo J. A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD). Basic Clin Pharmacol Toxicol. 2022;130:439\u201356.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3523_CR115","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","volume":"153","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199\u2013215.","journal-title":"Br J Pharmacol"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03523-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03523-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03523-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:02:43Z","timestamp":1781510563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03523-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":115,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3523"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03523-5","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. De Aquino has received research support from Jazz Pharmaceuticals and Ananda Scientific and has served as a paid consultant for Boehringer Ingelheim. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}